Inactive Instrument

SpectraCure AB (publ) Stock Nasdaq Stockholm

Equities

SE0007158118

Advanced Medical Equipment & Technology

Sales 2022 - Sales 2023 318K 29.12K Capitalization 375M 34.33M
Net income 2022 -25M -2.29M Net income 2023 -20M -1.83M EV / Sales 2022 -
Net cash position 2022 90.48M 8.28M Net cash position 2023 50.23M 4.6M EV / Sales 2023 1,021 x
P/E ratio 2022
-19.2 x
P/E ratio 2023
-18.3 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 77.13%
More Fundamentals * Assessed data
Dynamic Chart
Spectracure AB Continues in the Process of Initiating A Clinical Study, for Primary Localised Prostate Cancer CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
SpectraCure AB Conducts a Clinical Study for Patients with Recurrence of Prostate Cancer After Radiotherapy CI
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SpectraCure AB Decides to Seek Approval for Clinical Study of Primary Prostate Cancer CI
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
SpectraCure Receives an Additional EU Grant CI
SpectraCure AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
SpectraCure AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
SpectraCures Signs Letter of Intent with Cheplapharm CI
SpectraCure AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
SpectraCure AB(OM:SPEC) dropped from S&P Global BMI Index CI
SpectraCure Receives Patent Approval From EPO For Treatment Systems MT
European Patent Office Approves Spectracure AB's Patent Application Relating to the Technical Solution in the New Generation of Treatment Systems CI
SpectraCure AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 61 10-01-06
Director of Finance/CFO 66 18-03-31
Chief Tech/Sci/R&D Officer - 22-08-31
Members of the board TitleAgeSince
Founder 79 03-02-28
Director/Board Member 70 21-12-31
Chief Executive Officer 61 10-01-06
More insiders
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Calendar
More about the company